Sobi receives FDA approval for Gamifant to treat HLH/MAS

FDA approves Gamifant for macrophage activation syndrome in Still’s disease - Pharmafile

The US Food and Drug Administration (FDA) has approved Gamifant (emapalumab-lzsg) for the treatment of macrophage activation syndrome (MAS) in adult and paediatric patients with known or suspected Still’s disease, including systemic juvenile idiopathic arthritis. Announced by biopharma company Sobi, the approval makes Gamifant the first-ever FDA-approved therapy for MAS. The decision is based on […] The post FDA approves Gamifant for macrophage …

Sobi receives FDA approval for Gamifant to treat HLH/MAS

The FDA has approved Sobi's Gamifant (emapalumab) to treat adults and children with HLH/MAS associated with Still’s disease, including sJIA.